1. P524: PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML (KB-LANRA 1001). (23rd June 2022) Authors: Stein, E. M.; Patel, A.; Michaelis, L. C.; Schiller, G.; Swords, R.; Carvajal, L. A.; Bray, G.; DiMartino, J.; Levy, M. Y. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 423 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P525: PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ENTOSPLETINIB ADDED TO INTENSIVE INDUCTION AND CONSOLIDATION CHEMOTHERAPY IN NEWLY DIAGNOSED NPM1-MUTATED AML. (23rd June 2022) Authors: Byrd, J. C.; Cortes, J. E.; Minden, M. D.; Oellerich, T.; Stein, E. M.; Elder, J.; Kumar, P.; Bray, G.; DiMartino, J.; Stock, W. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 424 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗